

A 8

## POWER OF ATTORNEY FROM ASSIGNEE WITH DELEGATION

Octapharma AG, a corporation of Switzerland, having a principal place of business at Seidenstrasse 2, CH-8853 Lachen, Switzerland, is assignee of the entire right, title, and interest for the United States of America (as defined in 35 U.S.C. §100), by reason of an Assignment to the Assignee executed on October 16, 2002 of an invention known as **Protein Purification II** (Attorney Docket No. 2141.0030001/EEF/D-S [formerly 2081.0030001]), which is disclosed and claimed in a patent application of the same title by the inventor(s) Göran KARLSSON (said application filed on January 19, 2001 at the U.S. Patent and Trademark Office, having Application Number 09/766,098).

The Assignee hereby appoint the U.S. attorneys associated with **CUSTOMER NUMBER 28393** to prosecute this application and any continuation, divisional, continuation-in-part, or reissue application thereof, and to transact all business in the U.S. Patent and Trademark Office connected therewith, such attorneys currently being: Robert Greene Sterne, Registration No. 28,912; Edward J. Kessler, Esq., Registration No. 25,688; Jorge A. Goldstein, Esq., Registration No. 29,021; David K.S. Cornwell, Esq., Registration No. 31,944; Robert W. Esmond, Esq., Registration No. 32,893; Tracy-Gene G. Durkin, Esq., Registration No. 32,831; Michele A. Cimbala, Esq., Registration No. 33,851; Michael B. Ray, Esq., Registration No. 33,997; Robert E. Sokohl, Esq., Registration No. 36,013; Eric K. Steffe, Esq., Registration No. 36,688; Michael Q. Lee, Esq., Registration No. 35,239; Steven R. Ludwig, Esq., Registration No. 36,203; John M. Covert, Esq., Registration No. 38,759; Linda E. Alcorn, Esq., Registration No. 39,588; Lawrence B. Bugaisky, Esq., Registration No. 35,086; Donald J. Featherstone, Esq., Registration No. 33,876; and Robert C. Millonig, Esq., Registration No. 34,395. The Assignee hereby grants said attorneys the power to insert on this Power of Attorney any further identification that may be necessary or desirable in order to comply with the rules of the U.S. Patent and Trademark Office.

The Assignee hereby authorizes the U.S. attorneys named herein to accept and follow instructions from

Patentanwälte Von Kreisler Selting Werner

P.O. Box 10 22 41, D-50462 Köln (Cologne), GERMANY

as to any action to be taken in the U.S. Patent and Trademark Office regarding this application without direct communication between the U.S. attorneys and the Assignee. In the event of a change in the persons from whom instructions may be taken, the U.S. attorneys named herein will be so notified by the Assignee.

Send correspondence to:

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.  
1100 New York Avenue, N.W.  
Suite 600  
Washington, D.C. 20005-3934  
U.S.A.

Direct phone calls to 202-371-2600.

FOR: Octapharma AG

SIGNATURE: ✓

F. Leber

BY: ✓

Felix Lehner

TITLE: ✓

Sole member of Board of Directors

DATE: ✓

17 January 2003



Docket Number: 2141.0030001/EEF/D-S  
(formerly 2081.0030001)

### Certificate Under 37 C.F.R. § 3.73(b)

Applicant/Patent Owner: Göran KARLSSON

Application No./Patent No.: 09/766,098 Filed/Issue Date: January 19, 2001

Entitled: Protein Purification II

Octapharma AG

(Name of Assignee)

a Corporation

(Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

1. ☒ the assignee of the entire right, title, and interest, or
2. ☐ an assignee of an undivided part interest

in the patent application/patent identified above by virtue of either:

- A. ☐ An Assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the Patent and Trademark Office at Reel       , Frame       , or for which a copy thereof is attached.

OR

- B. ☒ A chain of title from the inventor(s) of the patent application/patent identified above to the current assignee as shown below:

1. From: Pharmacia & Upjohn AB To: Pharmacia AB

The document was recorded in the Patent and Trademark Office at  
Reel 013195, Frame 0295, or for which a copy thereof is attached.

2. From: Göran KARLSSON To: Pharmacia AB

The document was recorded in the Patent and Trademark Office at  
Reel 011730, Frame 0584, or for which a copy thereof is attached.

3. From: Pharmacia AB To: Biovitrum AB

The document was recorded in the Patent and Trademark Office at  
Reel 013195, Frame 0303, or for which a copy thereof is attached.

4. From: Biovitrum AB To: Octapharma AG

The document was recorded in the Patent and Trademark Office at  
Reel 013275, Frame 0373, or for which a copy thereof is attached.

☐ Additional documents in the chain of title are listed on a supplemental sheet.

☒ Copies of assignments or other documents in the chain of title are attached.

[NOTE: A separate copy (i.e., the original assignment document or a true copy of the original document) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the PTO. See MPEP 302-302.8]

The undersigned (whose title is supplied below) is empowered to act on behalf of the assignee.

Signature: Felix Lechner

Name: Felix Lechner

Title: Sole member of Board of Directors

Date: 17 January 2003

RECEIVED  
FEB 14 2003  
TECH CENTER 1600/2900

4477540


DO NOT FORWARD  
TO ASSIGNMENT BRANCH  
NOT FOR RECORDATION

#1

**PRV**

PATENT- OCH REGISTRERINGSVERKET  
Bolagsavdelningen

Page 1



**SWEDEN**

Registration number: 556131-9608  
Date of registration: 1969-12-30  
Company name: Pharmacia Aktiebolag  
Address:  
Registered office: 112 87 STOCKHOLM  
Stockholm  
Share capital: SEK 6.393.802.825

DO NOT FORWARD  
TO ASSIGNMENT BRANCH  
NOT FOR RECORDATION



**BOARD OF DIRECTORS:**

490724-5932 Alm, Harald Oskar Fredrik, Hollywoodvägen 16,  
191 77 SOLLENTUNA  
550602-0071 Berg, Nils Fredrik, Ehrenstrahlsvägen 62,  
168 51 BROMMA  
450401-4194 Håkansson, Nils Roland, (A), Lokvägen 25 F,  
260 33 PÅARP  
461008-4719 Persson, Gustav Lennart, (A), Gevärsgatan 1,  
262 62 ÄNGELHOLM  
491214-0326 Widén, Ingela Elisabet, (A), Skorpvägen 20,  
161 71 BROMMA  
470417-9193 Åström, Per Håkan Albin, (U), (O),  
126 Southern Boulevard, NJ 07928, CHATHAM NEW JER, USA

**DEPUTY MEMBERS OF THE BOARD:**

460401-1405 Johansson, Irene Linnéa Kristina, (A), Störvägen 23,  
756 47 UPPSALA  
520729-8588 Larsson, Lena Maria Catarina, (A), Lindhagensgatan 81,  
112 43 STOCKHOLM  
450107-5719 Mandrén, Ulf Holger, (A), Tegvägen 1,  
743 34 STORVRETA  
470721-1977 Wahlén, Hans Harald Wilhelm, Vasagatan 1C,  
753 13 UPPSALA

**MANAGING DIRECTOR:**

470417-9193 Åström, Per Håkan Albin, (U), (O),  
126 Southern Boulevard, NJ 07928, CHATHAM NEW JER, USA


**DEPUTY MANAGING DIRECTOR:**

550602-0071 Berg, Nils Fredrik, Ehrenstrahlsvägen 62,  
168 51 BROMMA

**OTHER PERSONS AUTHORIZED TO SIGN ON BEHALF OF THE COMPANY:**

560723-5131 Härfstrand, Karl Anders Olof, (U), Sibyllegatan 53,  
114 43 STOCKHOLM

CONTD.

**PRV**PATENT- OCH REGISTRERINGSVERKET  
Bolagsavdelningen

## SWEDEN

Registration number: 556131-9608  
 Date of registration: 1969-12-30  
 Company name: Pharmacia Aktiebolag  
 Address:  
 112 87 STOCKHOLM  
 Registered office: Stockholm  
 Share capital: SEK 6.393.802.825

490802-2520 Kilian, Patricia, Höguddsvägen 18 A, 181 62 LIDINGÖ  
 500126-0230 Lindqvist, Ulf Erik Åke, Bergshällsvägen 15,  
 187 34 TÄBY  
 520127-5012 Olving, Raoul Lennart, (U), Österplan 13,  
 753 31 UPPSALA  
 410109-8251 Sievertsson, Hans Uno, Rystavägen 5, 183 46 TÄBY  
 560906-4711 Svenberg, Anders Erik Gösta, Vansövägen 55,  
 125 40 ÄLVISJÖ  
 501002-1698 Weitzberg, Nathanael, Nockebyvägen 3, 167 71 BROMMA  
 500510-7056 Örström, Hans Erik Martin, Ersbackavägen 3,  
 816 30 OCKELBO

## COMPANY AUDITORS:

491031-9039 Bladh, Björn Peter Tommy, Fadderortsgränd 5,  
 165 72 HÄSSELBY  
 460515-0657 Tidström, Hans Göran, Knut Wallenbergs väg 39,  
 133 00 SALTSJÖBADEN

## DEPUTY AUDITORS:

571022-1101 Blom, Eva Mari, Odalvägen 6, 740 22 BÄLINGE  
 470411-7219 Danielsson, Åke Nils Gunnar, Neptunistigen 70,  
 162 40 VÄLLINGBY

## SIGNATORY POWER:

In addition to the Board of Directors,  
 any two jointly of


Alm, Harald Oskar Fredrik  
 Berg, Nils Fredrik  
 Åström, Per Håkan Albin  
 Härfstrand, Karl Anders Olof  
 Kilian, Patricia  
 Lindqvist, Ulf Erik Åke  
 Olving, Raoul Lennart  
 Sievertsson, Hans Uno  
 Svenberg, Anders Erik Gösta  
 Weitzberg, Nathanael

4477540

# PRV

PATENT- OCH REGISTRERINGSVERKET  
Bolagsavdelningen

Page 3



## SWEDEN

Registration number: 556131-9608  
Date of registration: 1969-12-30  
Company name: Pharmacia Aktiebolag  
Address:  
Registered office: 112 87 STOCKHOLM  
Stockholm  
Share capital: SEK 6.393.802.825

Örström, Hans Erik Martin  
are entitled to sign on behalf of the company.


Furthermore, the Managing Director, in his normal business  
activities, is also entitled to sign on behalf of the company.

SECONDARY NAMES:  
Citytappen

FINANCIAL YEAR:  
Registered financial year: 0101-1231  
Latest annual report submitted covers financial  
period 990101-991231

DATE OF REGISTRATION OF CURRENT AND PREVIOUS COMPANY NAMES:  
2000-09-28 Pharmacia Aktiebolag  
1996-07-01 Pharmacia & Upjohn Aktiebolag  
1993-11-17 Pharmacia Aktiebolag  
1984-12-27 Procordia Aktiebolag  
1969-12-30 Statsföretag Aktiebolag

SUNDSVALL 2000-10-11  
Ex officio

  
GUNN LAHTI



- (O) = chairman of the board
- (A) = employee representative
- (U) = person resident outside EEA
- (E) = person resident outside Sweden but within EEA

**DO NOT FORWARD  
TO ASSIGNMENT BRANCH  
NOT FOR RECORDATION**

Swedish Patent and Registration Office  
Companies Department  
S-851 81 SUNDSVALL  
Sweden

Schwedisches Patent- und Registeramt  
Gesellschaftsabteilung  
S-851 81 SUNDSVALL  
Schweden

Office Suédois des Brevets et de l'Enregistrement  
Section des Sociétés  
S-851 81 SUNDSVALL  
Suède

Tel: +46 60-18 40 00

Fax: +46 60-61 56 29

ASSIGNMENT

WHEREAS, I, **Göran KARLSSON**, a citizen of Sweden, residing at Björnidegränd 103, SE-162 46 Vällingby, Sweden (hereinafter referred to as "ASSIGNOR"), have invented **Protein Purification II**, for which U.S. Patent Application Serial No. 09/766,098 was filed on January 19, 2001; and

WHEREAS, **Pharmacia AB**, a corporation duly organized and existing under the laws of Sweden (hereinafter referred to as "ASSIGNEE"), is desirous of acquiring the entire interest therein:

NOW, THEREFORE, in consideration of good and valuable consideration, the receipt of which is hereby acknowledged, we, said ASSIGNOR, hereby sells, assigns, and transfers and set over, unto said ASSIGNEE, its successors, legal representatives and assigns, the entire right, title and interest in, to and under said invention, and said United States application and all divisions, renewals, and continuations thereof, and all Patents of the United States which may be granted thereon and all reissues, reexaminations and extensions thereof;

ASSIGNOR HEREBY authorizes and requests the Commissioner of Patents and Trademarks of the United States, and any Official whose duty it is to issue patents or other evidence or forms of industrial property protection on applications as aforesaid, to issue the same to said ASSIGNEE, its successors, legal representatives and assigns, in accordance with the terms of this instrument.

ASSIGNOR HEREBY grants the firm of DINSMORE & SHOHL LLP the power to insert in this Assignment any further identification or information which may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.

ASSIGNOR HEREBY covenants and agrees that he has full right to convey the entire interest herein assigned, and that they have not executed, and will not execute, any agreement in conflict herewith.

ASSIGNOR HEREBY further covenants and agrees that he will communicate to said ASSIGNEE, its successors, legal representatives and assigns, any facts known to them respecting said invention, and testify in any legal proceeding, sign all lawful papers, execute all divisional, continuing, reissue, reexamination and foreign applications, make all rightful oaths, and generally do everything possible to aid said ASSIGNEE, its successors, legal representatives and assigns, to obtain and enforce proper protection for said invention in the United States.

Dated: April 5, 2001

Göran Karlsson  
Göran Karlsson

**DO NOT FORWARD  
TO ASSIGNMENT BRANCH  
NOT FOR RECORDATION**

## ASSIGNMENT

In consideration of the sum of One Dollar (\$1.00) or equivalent and other good and valuable consideration, receipt of which is hereby acknowledged, **Pharmacia AB** a corporation organized and existing under the laws of Sweden and having an office and place of business at **SE-112 87 Stockholm, Sweden** (the "Assignor"), hereby sells and assigns to **Biovitrum AB** a corporation formed under the laws of Sweden, having an office and place of business at **Visitors Lindhagensgatan 133, SE-112 76 Stockholm, Sweden** (the "Assignee"), **100% (100 percent)** entire right, title and interest for the United States of America (as defined in 35 U.S.C. § 100), and throughout the world, including the right to sue for past infringement and to collect for all past, present and future damages,

(a) in each of the Patents and Patent Applications that are described in detail in Schedule A, annexed hereto and made a part hereof, and

(b) in any and all applications that claim the benefit of the Patents and Patent Applications described in detail in Schedule A, including continuing applications, reissues, extensions, renewals, and reexaminations of such Patents and Patent Applications, to the full extent of the term or terms for which Letters Patents issue, and

(c) in any and all inventions described in each of the Patents and Patent Applications that are described in detail on Schedule A, and in all forms of intellectual and industrial property protection derivable therefrom, and that are derivable from any and all continuing applications, reissues, extensions, renewals and reexaminations of such Patents and Patent Applications, including, without limitation, patents, applications, utility models, inventor's certificates, and designs together with the right to file applications therefor; and including the right to claim the same priority rights from any previously filed applications under the International Agreement for the Protection of Industrial Property, or any other international agreement, or the domestic laws of the country in which any such application is filed, as may be applicable;

all such rights, title and interest to be held and enjoyed by the above-named Assignee, its successors, legal representatives and assigns to the same extent as all such rights, title and interest would have been held and enjoyed by the Assignor had this assignment and sale not been made.

The Assignor agrees to execute all papers necessary in connection with the applications and Letters Patents as above, and any continuing (continuation, divisional, or continuation-in-part), reissue, reexamination or corresponding applications thereof and also to execute separate assignments in connection with such applications as the Assignee may deem necessary or expedient.

The Assignor agrees to execute all papers necessary in connection with any interference or patent enforcement action (judicial or otherwise) related to the applications or Letters Patents or any continuing (continuation, divisional, or continuation-in-part), reissue or reexamination application thereof and to cooperate with the Assignee at Assignee's expense in every reasonable way possible in obtaining evidence and going forward with such interference or patent enforcement act.

The Assignor agrees to perform all affirmative acts at Assignee's request and expense that may be necessary to obtain or ensure a grant of a valid patent to the Assignee.


The Assignor hereby represents that Assignor has full right and authority to convey the entire interest herein assigned, and that Assignor has not executed, and will not execute, any agreement in conflict therewith.

The Assignor hereby grants Robert Greene Sterne, Esquire, Registration No. 28,912; Edward J. Kessler, Esquire, Registration No. 25,688; Jorge A. Goldstein, Esquire, Registration No. 29,021; David K. S. Cornwell, Esquire, Registration No. 31,944; Robert W. Esmond, Esquire, Registration No. 32,893; Tracy-Gene G. Durkin, Esquire, Registration No. 32,831; Michele A. Cimbala, Esquire, Registration No. 33,851; Michael B. Ray, Esquire, Registration No. 33,997; Robert E. Sokohl, Esquire, Registration No. 36,013; Eric K. Steffe, Esquire, Registration No. 36,688; Michael Q. Lee, Esquire, Registration No. 35,239; Steven R. Ludwig, Esquire, Registration No. 36,203; John M. Covert, Esquire, Registration No. 38,759; Linda E. Alcorn, Esquire, Registration No. 39,588; Lawrence B. Bugaisky, Esquire, Registration No. 35,086; Donald J. Featherstone, Esquire, Registration No. 33,876; and Robert C. Millonig,



Esquire, Registration No. 34,395, all of STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C., 1100 New York Avenue, N.W., Suite 600, Washington, D.C. 20005-3934, power to insert in this assignment, including the attached Schedule A, any further information regarding the patents and patent applications so identified in such Schedule A that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.

SIGNED on behalf of the said ASSIGNOR, **PHARMACIA AB**

By: 

Agneta Tannerfeldt

[Type/Print Name]

Title: Director Global IP & Head

Date: Stockholm February 20, 2002

Witnessed before me:

Signature: 

Signature: 

Print Name: Birgitta Åkerman

Print Name: Birgitta Larsson

Address: Lollandsg 31, Kista Sweden

Address: Smedsbacksg 32, Stockholm Sweden

SIGNED on behalf of the said ASSIGNEE, **BIOVITRUM AB**

By:

  
Fredrik Berg

By:

  
Ulf Lindquist

[Type/Print Name]

Title: VP, General Counsel

Title: VP, Site Management

Date: Stockholm 11 February, 2002

Witnessed before me:

Signature: 

Signature: 

Print Name: Christina Ekroth

Print Name: Annette Hellman

Address: Bergsbovägen 11a, Eskilstuna Sweden

Address: Hämplingevägen 33, Älta, Sweden

DO NOT FORWARD  
TO ASSIGNMENT BRANCH  
NOT FOR RECORDATION

## SCHEDULE A

### UNITED STATES PATENTS, UNITED STATES PATENT APPLICATIONS AND INTERNATIONAL APPLICATIONS THAT DESIGNATE THE UNITED STATES

	Application No.	Filing Date	Patent No.	Issue Date
1.	09/766,098	Jan. 19, 2001	N/A	N/A

### OTHER INTERNATIONAL APPLICATIONS AND PATENTS

	Country	Application No.	Patent No.
1.	N/A		

**DO NOT FORWARD  
TO ASSIGNMENT BRANCH  
NOT FOR RECORDATION**

00012-V3  
00013-V3  
00877-V3  
PH-01870-V3  
PL-01870-V3

## ASSIGNMENT

In consideration of the sum of One Dollar (\$1.00) or equivalent and other good and valuable consideration, receipt of which is hereby acknowledged, Biovitrum AB a corporation organized and existing under the laws of Sweden and having an office and place of business at Visitors Lindhagensgatan 133, SE-112 76 Stockholm, Sweden (the "Assignor"), hereby sells and assigns to Octapharma AG a corporation formed under the laws of Switzerland, having an office and place of business at Seldenstrasse 2, CH-8853 Lachen, Switzerland (the "Assignee"), 100% (100 percent) entire right, title and interest for the United States of America (as defined in 35 U.S.C. § 100), and throughout the world, including the right to sue for past infringement and to collect for all past, present and future damages.

(a) in each of the Patents and Patent Applications that are described in detail in Schedule A, annexed hereto and made a part hereof, and

(b) in any and all applications that claim the benefit of the Patents and Patent Applications described in detail in Schedule A, including continuing applications, reissues, extensions, renewals, and reexaminations of such Patents and Patent Applications, to the full extent of the term or terms for which Letters Patents issue, and

(c) in any and all inventions described in each of the Patents and Patent Applications that are described in detail on Schedule A, and in all forms of intellectual and industrial property protection derivable therefrom, and that are derivable from any and all continuing applications, reissues, extensions, renewals and reexaminations of such Patents and Patent Applications, including, without limitation, patents, applications, utility models, inventor's certificates, and designs together with the right to file applications therefor; and including the right to claim the same priority rights from any previously filed applications under the International Agreement for the Protection of Industrial Property, or any other international agreement, or the domestic laws of the country in which any such application is filed, as may be applicable;

all such rights, title and interest to be held and enjoyed by the above-named Assignee, its successors, legal representatives and assigns to the same extent as all such rights, title and interest would have been held and enjoyed by the Assignor had this assignment and sale not been made.

The Assignor agrees to execute all papers necessary in connection with the applications and Letters Patents as above, and any continuing (continuation, divisional, or continuation-in-part), reissue, reexamination or corresponding applications thereof and also to execute separate assignments in connection with such applications as the Assignee may deem necessary or expedient.

The Assignor agrees to execute all papers necessary in connection with any interference or patent enforcement action (judicial or otherwise) related to the applications or Letters Patents or any continuing (continuation, divisional, or continuation-in-part), reissue or reexamination application thereof and to cooperate with the Assignee at Assignee's expense in every reasonable way possible in obtaining evidence and going forward with such interference or patent enforcement act.

The Assignor agrees to perform all affirmative acts at Assignee's request and expense that may be necessary to obtain or ensure a grant of a valid patent to the Assignee.

The Assignor hereby represents that Assignor has full right and authority to convey the entire interest herein assigned, and that Assignor has not executed, and will not execute, any agreement in conflict therewith.

The Assignor hereby grants Robert Greene Sterne, Esquire, Registration No. 28,912; Edward J. Kessler, Esquire, Registration No. 25,688; Jorge A. Goldstein, Esquire, Registration No. 29,021; David K. S. Cornwell, Esquire, Registration No. 31,944; Robert W. Esmond, Esquire, Registration No. 32,893; Tracy-Gene G. Durkin, Esquire, Registration No. 32,831; Michele A. Cimbala, Esquire, Registration No. 33,851; Michael B. Ray, Esquire, Registration No. 33,997; Robert E. Sokohl, Esquire, Registration No. 36,013; Eric K. Steffe, Esquire, Registration No. 36,688; Michael Q. Lee, Esquire, Registration No. 35,239; Steven R. Ladwig, Esquire, Registration No. 36,203; John M. Covert, Esquire, Registration No. 38,759; Linda E. Alcorn, Esquire, Registration No. 39,588; Lawrence B. Bugaisky, Esquire, Registration No. 35,086; Donald J. Featherstone, Esquire, Registration No. 33,876; and Robert C. Millonig, Esquire, Registration No. 34,395, all of STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C., 1100 New York Avenue, N.W., Suite

DO NOT FORWARD  
TO ASSIGNMENT BRANCH  
NOT FOR RECORDATION

600, Washington, D.C. 20005-3934, power to insert in this assignment, including the attached Schedule A, any further information regarding the patents and patent applications so identified in such Schedule A that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.

SIGNED on behalf of the said ASSIGNOR, Biovitrum AB

By:

Fredrik Berg  
SVP, General Counsel  
[Type/Print Name]

Ulf Lindquist  
VP, Site Management

Title:

Date:

2002 -10- 16

Witnessed before me:

Signature:

*Birgitta Larsson*

Print Name: Birgitta Larsson

Address: Novotullsgr. 120, 113 27

Stockholm  
Sweden

Signature:

*Pitwa Ander*

Print Name: Pitwa Ander

Address: Sjöbacken 47, 165 65 Hårselby

Sweden

SIGNED on behalf of the said ASSIGNEE, Octapharma AG

By:

[Type/Print Name]

Title:

Date:

Witnessed before me:

Signature:

Signature:

Print Name:

Print Name:

Address:

Address:

016PTO.wpt

1/15/01 10:00

ODMAVHODMA\SKGP\_DC157730.1

**SCHEDULE A****UNITED STATES PATENTS, UNITED STATES PATENT APPLICATIONS AND  
INTERNATIONAL APPLICATIONS THAT DESIGNATE THE UNITED STATES**

	<u>Application No.</u>	<u>Filing Date</u>	<u>Patent No.</u>	<u>Issue Date</u>	<u>Atty. Docket No.</u>
1.	09/598,883	21/06/2000			2081.0010001 PH-01870 US
2.	10/200,338	23/07/2002			2081.0010002 PH-01870 US
3.	09/986,464	08/11/2001			2081.0020001 00397 - US
4.	09/766,098	19/01/2001			2081.0030001 00013 - US
5.	09/776,887	19/01/2001			2081.0040001 00012 - US

**OTHER INTERNATIONAL APPLICATIONS AND PATENTS**

	<u>Country</u>	<u>Application No.</u>	<u>Patent No.</u>
1.			

**DO NOT FORWARD  
TO ASSIGNMENT BRANCH  
NOT FOR RECORDATION**

**ASSIGNMENT**

In consideration of the sum of One Dollar (\$1.00) or equivalent and other good and valuable consideration, receipt of which is hereby acknowledged, Blovitrum AB a corporation organized and existing under the laws of Sweden and having an office and place of business at Visitors Lindhagensgatan 133, SE-112 76 Stockholm, Sweden (the "Assignor"), hereby sells and assigns to Octapharma AG a corporation formed under the laws of Switzerland, having an office and place of business at Seidenstrasse 2, CH-8853 Lachen, Switzerland (the "Assignee"), 100% (100 percent) entire right, title and interest for the United States of America (as defined in 35 U.S.C. § 100), and throughout the world, including the right to sue for past infringement and to collect for all past, present and future damages,

(a) in each of the Patents and Patent Applications that are described in detail in Schedule A, annexed hereto and made a part hereof, and

(b) in any and all applications that claim the benefit of the Patents and Patent Applications described in detail in Schedule A, including continuing applications, reissues, extensions, renewals, and reexaminations of such Patents and Patent Applications, to the full extent of the term or terms for which Letters Patents issue, and

(c) in any and all inventions described in each of the Patents and Patent Applications that are described in detail on Schedule A, and in all forms of intellectual and industrial property protection derivable therefrom, and that are derivable from any and all continuing applications, reissues, extensions, renewals and reexaminations of such Patents and Patent Applications, including, without limitation, patents, applications, utility models, inventor's certificates, and designs together with the right to file applications therefor; and including the right to claim the same priority rights from any previously filed applications under the International Agreement for the Protection of Industrial Property, or any other international agreement, or the domestic laws of the country in which any such application is filed, as may be applicable;

all such rights, title and interest to be held and enjoyed by the above-named Assignee, its successors, legal representatives and assigns to the same extent as all such rights, title and interest would have been held and enjoyed by the Assignor had this assignment and sale not been made.

The Assignor agrees to execute all papers necessary in connection with the applications and Letters Patents as above, and any continuing (continuation, divisional, or continuation-in-part), reissue, reexamination or corresponding applications thereof and also to execute separate assignments in connection with such applications as the Assignee may deem necessary or expedient.

The Assignor agrees to execute all papers necessary in connection with any interference or patent enforcement action (judicial or otherwise) related to the applications or Letters Patents or any continuing (continuation, divisional, or continuation-in-part), reissue or reexamination application thereof and to cooperate with the Assignee at Assignee's expense in every reasonable way possible in obtaining evidence and going forward with such interference or patent enforcement act.

The Assignor agrees to perform all affirmative acts at Assignee's request and expense that may be necessary to obtain or ensure a grant of a valid patent to the Assignee.

The Assignor hereby represents that Assignor has full right and authority to convey the entire interest herein assigned, and that Assignor has not executed, and will not execute, any agreement in conflict therewith.

The Assignor hereby grants Robert Greene Sterne, Esquire, Registration No. 28,912; Edward J. Kessler, Esquire, Registration No. 25,688; Jorge A. Goldstein, Esquire, Registration No. 29,021; David K. S. Cornwell, Esquire, Registration No. 31,944; Robert W. Esmond, Esquire, Registration No. 32,893; Tracy-Gene G. Durkin, Esquire, Registration No. 32,831; Michele A. Cimbala, Esquire, Registration No. 33,851; Michael B. Ray, Esquire, Registration No. 33,997; Robert E. Sokohl, Esquire, Registration No. 36,013; Eric K. Steffe, Esquire, Registration No. 36,688; Michael Q. Lee, Esquire, Registration No. 35,239; Steven R. Ludwig, Esquire, Registration No. 36,203; John M. Covert, Esquire, Registration No. 38,759; Linda E. Alcorn, Esquire, Registration No. 39,588; Lawrence B. Bugalsky, Esquire, Registration No. 35,086; Donald J. Featherstone, Esquire, Registration No. 33,876; and Robert C. Millonig, Esquire, Registration No. 34,395, all of STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C., 1100 New York Avenue, N.W., Suite

600, Washington, D.C. 20005-3934, power to insert in this assignment, including the attached Schedule A, any further information regarding the patents and patent applications so identified in such Schedule A that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.

SIGNED on behalf of the said ASSIGNOR, Biovitrum AB

By: \_\_\_\_\_

[Type/Print Name]

Title: \_\_\_\_\_

Date: \_\_\_\_\_

Witnessed before me:

Signature: \_\_\_\_\_ Signature: \_\_\_\_\_

Print Name: \_\_\_\_\_ Print Name: \_\_\_\_\_

Address: \_\_\_\_\_ Address: \_\_\_\_\_

SIGNED on behalf of the said ASSIGNEE, Octapharma AG

By: ✓ J. Leuch **octapharma**

✓ Felix Leuchner Octapharma AG, Seidenstrasse 2  
[Type/Print Name] CH-8853 Lachen, Switzerland

Title: ✓ President

Date: ✓ October 11, 2002

Witnessed before me:

Signature: [Signature] Signature: D. Leuch

Print Name: Bettina Jopp Print Name: Ruth Leuch

Address: Octapharma AG Address: octapharma AG

016PTO.wps

::ODMA\MBODMA\SKGP\_DCI:37730:1

Seidenstr. 2  
CH-8853 Lachen

Seidenstr. 2  
CH-8853 Lachen

1/26/01 mac

**SCHEDULE A****UNITED STATES PATENTS, UNITED STATES PATENT APPLICATIONS AND  
INTERNATIONAL APPLICATIONS THAT DESIGNATE THE UNITED STATES**


	<u>Application No.</u>	<u>Filing Date</u>	<u>Patent No.</u>	<u>Issue Date</u>	<u>Atty. Docket No.</u>
1.	09/598,883	21/06/2000			2081.0010001
2.	10/200,338	23/07/2002			2081.0010002
3.	09/986,464	08/11/2001			2081.0020001
4.	09/766,098	19/01/2001			2081.0030001
5.	09/776,887	19/01/2001			2081.0040001

**OTHER INTERNATIONAL APPLICATIONS AND PATENTS**

	<u>Country</u>	<u>Application No.</u>	<u>Patent No.</u>
1.			

**DO NOT FORWARD  
TO ASSIGNMENT BRANCH  
NOT FOR RECORDATION**





Robert Greene Sterne  
Edward J. Kessler  
Jorge A. Goldstein  
David K.S. Cornwell  
Robert W. Esmond  
Tracy-Gene G. Durkin  
Michele A. Cimbala  
Michael B. Ray  
Robert E. Sokohl  
Eric K. Steffe  
Michael Q. Lee  
Steven R. Ludwig  
John M. Covert  
Linda E. Alcorn  
Robert C. Millonig  
Lawrence B. Bugaisky  
Donald J. Featherstone  
Michael V. Messinger

Judith U. Kim  
Timothy J. Shea, Jr.  
Patrick E. Garrett  
Jeffrey T. Helvey  
Heidi L. Kraus  
Edward W. Yee  
Albert L. Ferro  
Donald R. Banowit  
Peter A. Jackman  
Molly A. McCall  
Teresa U. Medler  
Jeffrey S. Weaver  
Kendrick P. Patterson  
Vincent L. Capuano  
Albert J. Fasulo II  
Eldora Ellison Floyd  
Thomas C. Fiala  
Brian J. Del Buono

Virgil Lee Beaston  
Kimberly N. Reddick  
Theodore A. Wood  
Elizabeth J. Haanes  
Bruce E. Chalker  
Joseph S. Ostroff  
Frank R. Cottingham  
Christine M. Uhler  
Rae Lynn Prengaman  
Jane Shershenovich  
Lawrence J. Carroll  
George S. Bardmesser  
Daniel A. Klein  
Rodney G. Maze  
Jason D. Eisenberg  
Michael A. Specht  
Andrea J. Kamage  
Tracy L. Muller

Jon E. Wright  
LuAnne M. Yuricek

**Registered Patent Agents\***  
Karen R. Markowicz  
Nancy J. Leith  
Ann E. Summerfield  
Helene C. Carlson  
Gaby L. Longworth  
Matthew J. Dowd  
Aaron L. Schwartz  
Angelique G. Uy  
Boris A. Matvenko  
Mary B. Tung  
Katrina Y. Pei  
Bryan L. Skelton  
Robert A. Schwartzman  
John J. Figueroa

1645  
Timothy A. Doyle  
Jennifer R. Mahalingappa  
Teresa A. Colella  
Jeffrey S. Lundgren  
Victoria S. Rutherford  
W. Brian Edge

**Senior Counsel**  
Samuel L. Fox  
Kenneth C. Bass III  
Lisa A. Dunner

\* Admitted only in Maryland  
\* Admitted only in Virginia  
\* Admitted only in Texas  
\* Practice Limited to  
Federal Agencies

February 11, 2003

Commissioner for Patents  
Washington, D.C. 20231

Re: U.S. Utility Patent Application  
Appl. No. 09/766,098; Filed: January 19, 2001  
For: **Protein Purification II**  
Inventor: Göran Karlsson  
Our Ref: 2141.0030001/EEF/D-S

Sir:

Transmitted herewith for appropriate action are the following documents:


1. SKGF Cover Letter;
2. Executed Certificate Under 37 C.F.R. § 3.73(b) with attached copies of chain of title documents (14 pages);
3. Executed Power of Attorney from Assignee with Delegation; and
4. One (1) return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

  
Eldora Ellison Floyd  
Attorney for Applicant  
Registration No. 39,967

EEF/DS/nef  
Enclosures  
::ODMA\HODMA\SKGF\_DC1;100698;1

SKGF Rev. 2/15/02 dcw